Results 11 to 20 of about 1,327 (120)
Oligoprogressive renal cell carcinoma: What is the role of surgery? [PDF]
BJU IntObjective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Re C +9 more
europepmc +2 more sources
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study
JTO Clinical and Research ReportsIntroduction: The patterns of oligoprogression after first-line immune checkpoint inhibitors (ICIs) for metastatic NSCLC are yet to be well established.
Harriet Gee +2 more
exaly +3 more sources
Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report. [PDF]
Thorac CancerSerial re‐biopsy in EGFR‐mutant NSCLC revealed sequential acquired EGFR T790M, MET c.3010C>G exon 14‐related alteration, and RET‐CCDC6 fusion. Mechanism‐guided therapy with almonertinib, almonertinib plus savolitinib, and later selpercatinib plus almonertinib with local radiotherapy achieved prolonged disease control, with survival approaching 50 ...
Zhu Y, Wang C, Hu NL, Wang DH, Wu SK.
europepmc +2 more sources
Diagnostics, 2023 Stereotactic ablative radiotherapy (SABR) may improve survival in patients with inoperable pulmonary oligometastases. However, the impact of pulmonary oligometastatic status after systemic therapy on SABR outcomes remains unclear.
Chia-Chun Kuo +2 more
exaly +3 more sources
Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives [PDF]
Current OncologyThe management of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after progression on osimertinib is becoming increasingly complex, particularly in Canada, where access to diagnostic testing and newer therapies ...
Nathalie Daaboul +16 more
doaj +2 more sources
First-line osimertinib in advanced [PDF]
ESMO Real World Data and Digital OncologyBackground: First-line osimertinib is standard for advanced EGFR -mutated non-small-cell lung cancer (NSCLC), but upfront combinations (FLAURA2, MARIPOSA) are reshaping this paradigm.
G. Suay +17 more
doaj +2 more sources
The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study [PDF]
Thoracic CancerBackground In metastatic non‐small cell lung cancer (NSCLC) patients receiving first‐line immune checkpoint inhibitors (ICIs), the real‐world progression patterns and subsequent treatment outcomes remain controversial. Methods We retrospectively analyzed
Qi He +8 more
doaj +2 more sources
Frontiers in Oncology, 2021 IntroductionImmune checkpoint inhibitors (ICIs) have changed the management of non-small cell lung cancer (NSCLC). However, resistance is inevitable.
Yanjun Xu, Hui Li, Yun Fan
doaj +1 more source
World Journal of Surgical Oncology, 2023 Background Oligoprogression is an emerging issue in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Pang-Shuo Perng +10 more
doaj +1 more source
Exploration of Targeted Anti-tumor Therapy, 2023 Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival.
Sviatoslav Chekhun +11 more
doaj +1 more source